{"listing":{"listing_type":"company","name":"Microbiotica","slug":"microbiotica","tagline":"Clinical-stage precision microbiome medicines for ulcerative colitis and cancer","description":"Microbiotica is a clinical-stage biopharma company near Cambridge, UK, spun out of the Wellcome Sanger Institute in 2016, developing orally dosed live biotherapeutic products. Its genomics-driven platform combines a gut microbiome culture collection, a proprietary reference genome database, bioinformatics and machine learning to identify bacteria associated with favourable clinical trial outcomes. Lead programme MB310, an eight-strain once-daily oral therapy for ulcerative colitis, met its Phase 1b endpoints, and MB097 is being developed with KEYTRUDA for advanced melanoma. On 16 October 2026 Microbiotica announced a £36 million ($48 million) Series C first close led by British Business Bank with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners to take MB310 into Phase 2.","url":"https://microbiotica.com/","is_stealth":false,"normalized_domain":"microbiotica.com","normalized_url_key":"microbiotica.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Favicon_RGB.png","links":[{"label":"X / Twitter","url":"https://x.com/MicrobioticaLtd","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/microbiotica-limited/","platform":"linkedin"},{"label":"Series C press release","url":"https://microbiotica.com/microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"blog","url":"https://microbiotica.com/press-releases/","audience":"human","label":"Press releases","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"careers","url":"https://microbiotica.com/working-here/","audience":"human","label":"Working here","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/pipeline/","audience":"human","label":"Pipeline","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/platform/","audience":"human","label":"Platform","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c773eb05-0d47-4a1e-b2ed-7e27bef55b56"},"categories":["Biotech","Microbiome","Drug Development","Healthcare"],"stage":"series-b+","founded_year":null,"location":"Cambridge, United Kingdom","pricing":null,"twitter":"https://x.com/MicrobioticaLtd","github":null,"linkedin":"https://www.linkedin.com/company/microbiotica-limited/","contact_email":null,"added_at":"2026-10-16T22:40:16.996Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T22:40:16.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"microbiome","name":"Microbiome","note":null,"profile_url":"/industries/microbiome"}]}}